Skip to main content
SpringerLink
Log in

A randomized phase II evaluation of bryostatin-1 (NSC #339555) in recurrent or persistent platinum-sensitive ovarian cancer: A Gynecologic Oncology Group Study

  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Abstract

Objectives. The Gynecologic Oncology Group (GOG) performed a randomized phase II study to determine the antitumor activity and toxicity of two different schedules of bryostatin-1 administration in patients with recurrent or persistent platinum-sensitive epithelial ovarian cancer or primary peritoneal carcinoma. Methods. Eligible patients were randomized to receive either bryostatin-1 25μg/m2 as a 1h infusion weekly for 3 weeks followed by a 1-week rest (Regimen I) or bryostatin-1 120μg/m2 as a 72h continuous infusion every 2 weeks (Regimen II). Results. Fifty-five patients were enrolled on this study. There was one durable response among 27 eligible patients (response rate=3.7%) on Regimen II and no responses in the 27 eligible patients on Regimen I. Nineteen patients (eleven on Regimen I and eight on Regimen II) had stable disease. The most common adverse event was myalgia, with 12 of 27 patients (44%) on each regimen experiencing some degree of myalgia. There were no other significant toxicities on either treatment arm. Conclusions. Both of these schedules and doses of bryostatin-1 are inactive as single agents in previously treated epithelial ovarian cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M: Cancer statistics. CA Cancer J Clin 51(1): 15–36, 2001

    Google Scholar 

  2. Ozols RF, Rubin SC, Thomas G, Robboy S: Epithelial ovarian cancer. In: Hoskins WJ, Perez CA, Young RC (eds) Principles and Practice of Gynecologic Oncology, 2nd edn. Lippincott-Raven, Philadalphia, PA, 1997, pp 919–986

    Google Scholar 

  3. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334(1): 1–6, 1996

    Google Scholar 

  4. Pettit GR, Herald CL, Doubek DL, Herald D: Isolation and structure of bryostatin-1. J Am Chem Soc 104: 6846–6848, 1982

    Google Scholar 

  5. Mutter R, Wills M: Chemistry and clinical biology of the bryostatins. Bioorg Med Chem 8(8): 1841–1860, 2000

    Google Scholar 

  6. Philip PA, Zonder JA: Pharmacology and clinical experience with bryostatin-1: a novel anticancer drug. Expert Opin Investig Drugs 8(12): 2189–2199, 1999

    Google Scholar 

  7. Prendiville J, Crowther D, Thatcher N, Woll PJ, Fox BW, McGown A, Testa N, Stern P, McDermott R, Potter M: A phase I study of intravenous bryostatin-1 in patients with advanced cancer. Br J Cancer 68(2): 418–424, 1993

    Google Scholar 

  8. O'Reilly S, Slichenmyer W, Hess A, Donehower R: A phase I and immunologic study of bryostatin-1 in patients with solid tumors. Proc Amer Assoc Cancer Res 56: 802–808, 1996

    Google Scholar 

  9. Barry OP, Kazanietz MG: Protein kinase c isozymes, novel phorbol ester receptors and cancer chemotherapy. Curr Pharm Des 7(17): 1725–1744, 2001

    Google Scholar 

  10. Carter CA: Protein kinase C as a drug target: implications for drug or diet prevention and treatment of cancer. Curr Drug Targets 1(2): 163–183, 2000

    Google Scholar 

  11. Basu A, Lazo JS: Sensitization of human cervical carcinoma cells to cisdiamminedichloroplatinum (II) by bryostatin-1. Cancer Res 52(11): 3119–3124, 1992

    Google Scholar 

  12. Wang S, Wang Z, Boise LH, Dent P, Grant S: Bryostatin-1 enhances paclitaxel induced mitochondrial dysfunction and apoptosis in human leukemia cells (U927) ectopically expressing Bcl-xL. Leukemia 13(10): 1564–1573, 1999

    Google Scholar 

  13. Koutcher JA, Motwani M, Zakian KL, Li XK, Matei C, Dyke JP, Ballon D, Yoo HH, Schwartz GK: The in vivo effect of bryostatin-1 on paclitaxel-induced tumor growth, mitotic entry, and blood flow. Clin Cancer Res 6(4): 1498–1507, 2000

    Google Scholar 

  14. Mohammad RM, Wall NR, Dutcher JA, Al-Katib AM: The addition of bryostatin-1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model. Clin Cancer Res 6(12): 4950–4956, 2000

    Google Scholar 

  15. Zaugg K, Rocha S, Resch H, Hegyi I, Oehler C, Glanzmann C, Fabbro D, Bodis S, Pruschy M: Differential p53–dependent mechanism of radiosensitization in vitro and in vivo by the protein kinase C-specific inhibitor PKC412. Cancer Res 61(2): 832–838, 2001

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Oncology, Gynecology, and Obstetrics, Sidney Kimmal Comprehensive Cancer Centèr John Hopkins, Baltimore, MD, 21231, U.S.A

    Deborah K. Armstrong (Assistant Professor)

  2. Gynecologic Oncology Group Statistical and Data Center, Roswell Park Cancer Institute, Buffalo, NY, 14263, U.S.A

    John A. Blessing (Executive Director)

  3. Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, Indiana University School of Medicine, Indianapolis, IN, 46202, U.S.A

    Katherine Y. Look (Professor)

  4. Fox Chase Cancer Center, Department of Medical Oncology, Philadelphia, PA, 19111, U.S.A

    Russell Schilder (Member)

  5. Tufts University School of Medicine, Boston, MA, 02111, U.S.A

    Evelyn R. Nunez (Assistant Professor of Obstetrics and Gynecology)

Authors
  1. Deborah K. Armstrong
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John A. Blessing
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Katherine Y. Look
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Russell Schilder
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Evelyn R. Nunez
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Armstrong, D.K., Blessing, J.A., Look, K.Y. et al. A randomized phase II evaluation of bryostatin-1 (NSC #339555) in recurrent or persistent platinum-sensitive ovarian cancer: A Gynecologic Oncology Group Study. Invest New Drugs 21, 373–377 (2003). https://doi.org/10.1023/A:1025490818450

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1025490818450

Search

Navigation